Table 1: Studies Investigating the Prognostic Value of sST2 in HFpEF.

Study and Year	n	Type of Analysis	LVEF	Outcome
Shah et al. 2011[47]	200	Post hoc	≥50%	Association between increased baseline sST2 levels and increased 1-year mortality (p=0.001)
Manzano-Fernández et al. 2011[48]	197	Retrospective	≥50%	Association between increased baseline sST2 levels and increased 1-year mortality (p=0.002)
Friões et al. 2015[52]	76	Retrospective	≥50%	No association between increased sST2 levels measured at discharge after hospitalisation for ADHF and a composite endpoint of all-cause death or hospital readmission for HF within 6 months (p=0.07)
Sanders-van Wijk et al. 2015[49]	100	Post hoc	≥50%	Association between increased baseline sST2 levels and decreased 18-month overall survival and HF hospitalisation-free survival (p=0.002)
Moliner et al. 2018[53]	135	Retrospective	≥50%	No association between increased baseline sST2 levels and cardiovascular death or HF-related hospitalisation (p=0.79) and all-cause death or HF-related hospitalisation (p=0.44; mean follow-up period 4.9 ± 2.8 years)
Najjar et al. 2019[50]	86	Retrospective	≥45%	Association between increased sST2 levels 4–8 weeks (stable condition) after enrolment and a composite endpoint of death or HF hospitalisation (median follow-up of 522 days; p=0.046)
Sugano et al. 2019[51]	191	Post hoc	≥50%	Association between increased baseline sST2 levels and increased all-cause death and non- cardiovascular death (median follow-up 445 days; p=0.002, p=0.003)

ADHF = acute decompensated heart failure; HF = heart failure; HFpEF = heart failure with preserved ejection fraction; LVEF = left ventricular ejection fraction; sST2 = soluble suppression of tumourigenicity 2.